Study of MT-6402 in Subjects With Advanced Solid Cancer That Expresses PD-L1
Status:
Recruiting
Trial end date:
2026-05-01
Target enrollment:
Participant gender:
Summary
This will be a Phase 1 Open-label, dose escalation and expansion study of MT-6402 (an
Engineered Toxin Body (ETB)) in subjects with advanced solid cancer that expresses PD-L1